









市场行情
/
股票
/
nasdaq-rytm
/

Rhythm Pharmaceuticals Inc

RYTM

108.750USD

+2.170+2.04%

收盘 11/25, 16:00（美东）报价延迟15分钟

7.25B总市值

亏损市盈率 TTM



Rhythm Pharmaceuticals Inc

108.750

+2.170+2.04%

概览公司财务分析

概览

公司

财务

分析

关于 Rhythm Pharmaceuticals Inc 公司

Rhythm Pharmaceuticals, Inc. 是一家商业阶段的生物制药公司。该公司专注于推进其黑皮质素-4 受体 (MC4R) 激动剂，包括其主要资产 IMCIVREE，这是一种精准医疗，旨在治疗由罕见的 MC4R 通路疾病引起的暴食症和严重肥胖症。IMCIVREE 已获得美国食品药品管理局 (FDA) 批准，用于治疗因阿片黑皮质素原 (POMC)、前蛋白转化酶枯草溶菌素/kexin 1 型 (PCSK1) 或瘦素受体 (LEPR) 缺乏而导致的单基因或综合征性肥胖的成人和 6 岁及以上的儿童患者的慢性体重管理，经 FDA 批准的测试确定，POMC、PCSK1 或 LEPR 基因中的变异被解释为致病、可能致病或意义不明 (VUS)；或 Bardet-Biedl 综合征 (BBS)。该公司正在 II 期和 III 期试验中评估 setmelanotide 对治疗因与 MC4R 通路相关的众多基因之一变异而导致的肥胖症的效果。

Rhythm Pharmaceuticals Inc简介



公司代码RYTM

公司名称Rhythm Pharmaceuticals Inc

上市日期Oct 05, 2017

CEO- -

员工数量283

证券类型Ordinary Share

年结日Oct 05

公司地址222 Berkeley Street

城市BOSTON

上市交易所NASDAQ Global Market Consolidated

国家United States of America

邮编02116

电话18572644280

网址https://rhythmtx.com/

公司代码RYTM

上市日期Oct 05, 2017

CEO- -

Rhythm Pharmaceuticals Inc公司高管



名称

名称/职务

职务

持股

持股变动

Dr. David P. Meeker ,M.D.

Chairman of the Board, President, Chief Executive Officer

201.82K

Mr. Hunter C. Smith

Chief Financial Officer, Treasurer

116.92K

Mr. Yann Mazabraud

Executive Vice President, Head of International

37.66K

-6.73%

Mr. Joseph (Joe) Shulman

Chief Technical Officer

8.51K

Ms. Jennifer L. Good

Independent Director

7.00K

+133.33%

Mr. Christophe R. Jean

Independent Director

7.00K

+133.33%

Dr. Camille L. Bedrosian, M.D.

Independent Director

7.00K

+133.33%

Mr. Stuart A. Arbuckle

Independent Director

7.00K

+133.33%

Ms. Lynn A. Tetrault, J.D.

Independent Director

Dr. Alastair (Al) Garfield, Ph.D.

Chief Scientific Officer

名称

名称/职务

职务

持股

持股变动

Dr. David P. Meeker ,M.D.

Chairman of the Board, President, Chief Executive Officer

201.82K

Mr. Hunter C. Smith

Chief Financial Officer, Treasurer

116.92K

Mr. Yann Mazabraud

Executive Vice President, Head of International

37.66K

-6.73%

Mr. Joseph (Joe) Shulman

Chief Technical Officer

8.51K

Ms. Jennifer L. Good

Independent Director

7.00K

+133.33%

Mr. Christophe R. Jean

Independent Director

7.00K

+133.33%

收入明细

单位: USD更新时间: 10月6日周一

FY2024

FY2023

FY2022

FY2021

由于公司未披露，未能获取相关数据

地区USD

名称

营收

占比

United States

96.11M

73.86%

International

34.02M

26.14%

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月15日周六

持股股东

股东类型

持股股东

占比

RA Capital Management, LP

8.51%

Baker Bros. Advisors LP

8.40%

The Vanguard Group, Inc.

7.47%

PRIMECAP Management Company

6.39%

BlackRock Institutional Trust Company, N.A.

5.88%

其他

63.35%

持股股东

占比

RA Capital Management, LP

8.51%

Baker Bros. Advisors LP

8.40%

The Vanguard Group, Inc.

7.47%

PRIMECAP Management Company

6.39%

BlackRock Institutional Trust Company, N.A.

5.88%

其他

63.35%

股东类型

持股股东

占比

Investment Advisor

39.63%

Investment Advisor/Hedge Fund

30.37%

Hedge Fund

15.95%

Venture Capital

13.66%

Research Firm

4.00%

Private Equity

3.98%

Bank and Trust

0.75%

Individual Investor

0.67%

Pension Fund

0.44%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

461

70.26M

105.28%

-843.23K

2025Q2

451

66.54M

100.20%

-6.36M

2025Q1

464

66.24M

104.13%

-6.91M

2024Q4

438

66.17M

104.69%

-7.75M

2024Q3

414

68.98M

112.28%

-7.86M

2024Q2

402

70.62M

115.59%

-5.66M

2024Q1

385

68.75M

112.78%

-8.84M

2023Q4

369

67.33M

113.30%

-8.52M

2023Q3

350

68.72M

116.31%

-2.96M

2023Q2

327

67.69M

118.97%

+564.21K

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

RA Capital Management, LP

5.56M

8.37%

-523.05K

-8.60%

Jun 30, 2025

Baker Bros. Advisors LP

5.60M

8.44%

Jun 30, 2025

The Vanguard Group, Inc.

3.58M

5.39%

+144.19K

+4.20%

Jun 30, 2025

PRIMECAP Management Company

4.88M

7.34%

-909.28K

-15.71%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

3.91M

5.88%

-93.66K

-2.34%

Jun 30, 2025

New Enterprise Associates (NEA)

2.91M

4.38%

Jun 30, 2025

Perceptive Advisors LLC

2.42M

3.64%

-130.15K

-5.11%

Jun 30, 2025

Fidelity Management & Research Company LLC

1.91M

2.87%

+272.55K

+16.66%

Jun 30, 2025

State Street Investment Management (US)

1.91M

2.87%

-63.13K

-3.20%

Jun 30, 2025

Goldman Sachs & Company, Inc.

1.60M

2.41%

+37.94K

+2.43%

Jun 30, 2025

持股ETF



更新时间: 11月6日周四

机构名称

占比

Innovator IBD 50 Fund ETF

4.21%

ALPS Medical Breakthroughs ETF

4.11%

Virtus LifeSci Biotech Products ETF

2.67%

Harbor Human Capital Factor US Small Cap ETF

1.97%

Roundhill GLP-1 & Weight Loss ETF

1.88%

Harbor Health Care ETF

1.8%

iShares Health Innovation Active ETF

1.79%

Invesco Dorsey Wright Healthcare Momentum ETF

1.5%

SPDR S&P Biotech ETF

1.45%

First Trust Multi-Manager Small Cap Opportunities ETF

0.76%

Innovator IBD 50 Fund ETF

占比4.21%

ALPS Medical Breakthroughs ETF

占比4.11%

Virtus LifeSci Biotech Products ETF

占比2.67%

Harbor Human Capital Factor US Small Cap ETF

占比1.97%

Roundhill GLP-1 & Weight Loss ETF

占比1.88%

Harbor Health Care ETF

占比1.8%

iShares Health Innovation Active ETF

占比1.79%

Invesco Dorsey Wright Healthcare Momentum ETF

占比1.5%

SPDR S&P Biotech ETF

占比1.45%

First Trust Multi-Manager Small Cap Opportunities ETF

占比0.76%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Rhythm Pharmaceuticals Inc的前五大股东是谁？



Rhythm Pharmaceuticals Inc 的前五大股东如下：
RA Capital Management, LP持有股份：5.56M，占总股份比例：8.37%。
Baker Bros. Advisors LP持有股份：5.60M，占总股份比例：8.44%。
The Vanguard Group, Inc.持有股份：3.58M，占总股份比例：5.39%。
PRIMECAP Management Company持有股份：4.88M，占总股份比例：7.34%。
BlackRock Institutional Trust Company, N.A.持有股份：3.91M，占总股份比例：5.88%。